Skip to main content
Fig. 4 | Cancer & Metabolism

Fig. 4

From: A small-molecule pan-class I glucose transporter inhibitor reduces cancer cell proliferation in vitro and tumor growth in vivo by targeting glucose-based metabolism

Fig. 4

Chronic effects of DRB18 in A549 cancer cells (72 h). The chronic effects of the DRB18 treatment were investigated by using ATP assay, cell cycle analysis, ROS assay and western blot in 72-h-treated cells. All values are relative to mock-treated controls. Values represented are mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001. a DRB18 reduced intracellular ATP levels in A549 cells. b DRB18 increased the percentage of cells in the G1 phase of the cell cycle and reduces them in the S phase. c DRB18 induced the increase in ROS levels. d DRB18 induced the increase in the number of necrotic cells in flow cytometry analysis. e DRB18 treatment reduced expression of GLUT1-4 at the protein level. f Quantification of western blot results is shown in (e). Cofilin was used a control

Back to article page

Cancer & Metabolism

ISSN: 2049-3002